<?xml version='1.0' encoding='utf-8'?>
<document id="31440161"><sentence text="Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin-Angiotensin System Inhibitors: The Detection of Signals of Drug-Drug Interactions."><entity charOffset="74-86" id="DDI-PubMed.31440161.s1.e0" text="Valacyclovir" /></sentence><sentence text="Background: Drug-related acute kidney disease is a common side effect of valacyclovir (VACV) treatment"><entity charOffset="73-85" id="DDI-PubMed.31440161.s2.e0" text="valacyclovir" /><entity charOffset="87-91" id="DDI-PubMed.31440161.s2.e1" text="VACV" /><pair ddi="false" e1="DDI-PubMed.31440161.s2.e0" e2="DDI-PubMed.31440161.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31440161.s2.e0" e2="DDI-PubMed.31440161.s2.e1" /></sentence><sentence text=" Although analgesics are frequently administered concomitantly with VACV to treat the pain of herpes zoster, the differences between nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen in relation to VACV-related acute kidney injury (AKI) are unclear"><entity charOffset="183-196" id="DDI-PubMed.31440161.s3.e0" text="acetaminophen" /><entity charOffset="68-80" id="DDI-PubMed.31440161.s3.e1" text="VACV" /><entity charOffset="212-224" id="DDI-PubMed.31440161.s3.e2" text="VACV" /><pair ddi="false" e1="DDI-PubMed.31440161.s3.e1" e2="DDI-PubMed.31440161.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31440161.s3.e1" e2="DDI-PubMed.31440161.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31440161.s3.e1" e2="DDI-PubMed.31440161.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31440161.s3.e0" e2="DDI-PubMed.31440161.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31440161.s3.e0" e2="DDI-PubMed.31440161.s3.e2" /></sentence><sentence text=" The risk for AKI with concomitant use of VACV and renin-angiotensin system (RAS) inhibitors that can cause AKI via a similar mechanism to NSAIDs is also unknown"><entity charOffset="42-45" id="DDI-PubMed.31440161.s4.e0" text="VACV" /></sentence><sentence text=" We therefore evaluated the association between concomitant use of these drugs and VACV-related AKI, which was characterized according to the Japanese Adverse Drug Event Report (JADER) database"><entity charOffset="83-86" id="DDI-PubMed.31440161.s5.e0" text="VACV" /></sentence><sentence text=" Methods: We analyzed data from the JADER database, which is a spontaneous reporting system" /><sentence text=" The reporting odds ratio was used to evaluate the signals of AKI" /><sentence text=" Results: A high proportion of VACV-related AKI cases occurred in summer"><entity charOffset="31-34" id="DDI-PubMed.31440161.s8.e0" text="VACV" /></sentence><sentence text=" There was an increase in AKI signal in cases with concomitant use of VACV and NSAIDs, while no increase was detected in cases with concomitant use of VACV and acetaminophen"><entity charOffset="151-155" id="DDI-PubMed.31440161.s9.e0" text="VACV" /><entity charOffset="160-173" id="DDI-PubMed.31440161.s9.e1" text="acetaminophen" /><entity charOffset="70-82" id="DDI-PubMed.31440161.s9.e2" text="VACV" /><pair ddi="false" e1="DDI-PubMed.31440161.s9.e2" e2="DDI-PubMed.31440161.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31440161.s9.e2" e2="DDI-PubMed.31440161.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31440161.s9.e2" e2="DDI-PubMed.31440161.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31440161.s9.e0" e2="DDI-PubMed.31440161.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31440161.s9.e0" e2="DDI-PubMed.31440161.s9.e1" /></sentence><sentence text=" AKI events in cases with concomitant use of VACV and NSAIDs were more frequent in older and female patients and those with hypertension"><entity charOffset="45-48" id="DDI-PubMed.31440161.s10.e0" text="VACV" /></sentence><sentence text=" Additionally, a signal increase for VACV-related AKI was observed with concomitant use of RAS inhibitors, with or without NSAIDs"><entity charOffset="37-40" id="DDI-PubMed.31440161.s11.e0" text="VACV" /></sentence><sentence text=" Conclusions: We identified a seasonal variation in VACV-related AKI"><entity charOffset="52-55" id="DDI-PubMed.31440161.s12.e0" text="VACV" /></sentence><sentence text=" Additionally, our findings indicate that acetaminophen might represent a safer analgesic than NSAIDs with respect to VACV-related AKI"><entity charOffset="42-55" id="DDI-PubMed.31440161.s13.e0" text="acetaminophen" /><entity charOffset="118-130" id="DDI-PubMed.31440161.s13.e1" text="VACV" /><pair ddi="false" e1="DDI-PubMed.31440161.s13.e0" e2="DDI-PubMed.31440161.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31440161.s13.e0" e2="DDI-PubMed.31440161.s13.e1" /></sentence><sentence text=" We also identified candidate risk factors for AKI with concomitant use of NSAIDs, such as older age, female sex, and hypertension" /><sentence text=" Although further studies are warranted, our findings highlight the need to consider concomitant drug use and seasonal factors that lead to urinary output loss so that VACV-related AKI can be avoided"><entity charOffset="168-171" id="DDI-PubMed.31440161.s15.e0" text="VACV" /></sentence><sentence text="" /></document>